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cQueen Elizabeth Hospital, University Hospital Birmingham,
West Midlands, UKAbstract—In Parkinson’s disease (PD), elevated beta
(15–35 Hz) power in subcortical motor networks is widely
believed to promote aspects of PD symptomatology, more-
over, a reduction in beta power and coherence accompanies
symptomatic improvement following eﬀective treatment
with L-DOPA. Previous studies have reported symptomatic
improvements that correlate with changes in cortical net-
work activity following GABAA receptor modulation. In this
study we have used whole-head magnetoencephalography
to characterize neuronal network activity, at rest and during
visually cued ﬁnger abductions, in unilaterally symptomatic
PD and age-matched control participants. Recordings were
then repeated following administration of sub-sedative
doses of the hypnotic drug zolpidem (0.05 mg/kg), which
binds to the benzodiazepine site of the GABAA receptor. A
beamforming based ‘virtual electrode’ approach was used
to reconstruct oscillatory power in the primary motor cortex
(M1), contralateral and ipsilateral to symptom presentation
in PD patients or dominant hand in control participants. In
PD patients, contralateral M1 showed signiﬁcantly greater
beta power than ipsilateral M1. Following zolpidem adminis-
tration contralateral beta power was signiﬁcantly reduced
while ipsilateral beta power was signiﬁcantly increased
resulting in a hemispheric power ratio that approached par-
ity. Furthermore, there was highly signiﬁcant correlation
between hemispheric beta power ratio and Uniﬁed Parkin-
son’s Disease Rating Scale (UPDRS). The changes in
contralateral and ipsilateral beta power were reﬂected in
pre-movement beta desynchronization and the late post-
movement beta rebound. However, the absolute level ofhttp://dx.doi.org/10.1016/j.neuroscience.2014.09.037
0306-4522/ 2014 The Authors. Published by Elsevier Ltd. on behalf of IBRO.
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68movement-related beta desynchronization was not altered.
These results show that low-dose zolpidem not only
reduces contralateral beta but also increases ipsilateral
beta, while rebalancing the dynamic range of M1 network
oscillations between the two hemispheres. These changes
appear to underlie the symptomatic improvements aﬀorded
by low-dose zolpidem.  2014 The Authors. Published by
Elsevier Ltd. on behalf of IBRO. This is anopenaccess article
under theCCBY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/3.0/).
Key words: magnetoencephalography, Parkinson’s disease,
primary motor cortex, beta oscillations, GABAA receptors.
INTRODUCTION
Physiological neuronal network oscillations at beta
frequency (15–35 Hz) occur spontaneously in the
primary motor cortex (M1) of humans (Jensen et al.,
2005; Hall et al., 2010a) and in animal models (Murthy
and Fetz, 1996; Baker et al., 1997). The possible func-
tional signiﬁcance of beta oscillations is reﬂected by the
power changes that occur during the various phases of
movement. In self-paced movement, the pre-movement
period is characterized by a bilateral reduction in the
power of the spontaneous beta activity (Pfurtscheller
and Berghold, 1989; Leocani et al., 1997; Jurkiewicz
et al., 2006) up to two-seconds prior to movement initia-
tion. Following this, whether self-paced or externally cued,
there is a further bilateral reduction in beta power, referred
to as movement-related beta desynchronization (MRBD)
(Gaetz et al., 2011; Hall et al., 2011). Following move-
ment termination, an increase in beta oscillatory power
above the pre-movement baseline amplitude is observed
(Pfurtscheller et al., 1996), a phenomenon referred to as
post-movement beta rebound (PMBR).
In Parkinson’s disease (PD) exaggerated beta
oscillations are observed in recordings from subcortical
structures such as the subthalamic nucleus (STN) and
cortex of both animal models (Sharott et al., 2005; Chen
et al., 2007; Mallet et al., 2008) and PD patients
(Cassidy et al., 2002; Pollok et al., 2012). Similarly, several
studies report that this elevated beta power and coher-
ence is attenuated following treatment with either L-DOPA
(Silberstein et al., 2005; Kuhn et al., 2006) or deep brain
stimulation (Ku¨hn et al., 2008; Eusebio et al., 2011), both
of which are associated with relief of PD symptoms.
A number of reports have highlighted that sub-
sedative doses (2–5 mg) of the GABAA receptorons.org/licenses/by-nc-nd/3.0/).
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cognitive and motor abilities of patients in persistent
vegetative state (Clauss and Nel, 2006), brain injury
(Cohen et al., 2004; Shames and Ring, 2008), dementia
(Jarry et al., 2002) and idiopathic PD (Daniele et al.,
1997; Chen et al., 2008; Huang et al., 2012). However,
the mechanism underlying such beneﬁts remains to be
elucidated.
Our own previous study with a brain-injured
participant revealed persistent pathological theta
(4–10 Hz) and beta (15–35 Hz) oscillations in cortical
areas surrounding the lesion (Hall et al., 2010b). Speciﬁ-
cally, sensorimotor and language areas exhibited patho-
logical beta and theta, consistent with altered gait and
speech agnosia. Zolpidem greatly reduced the synchro-
nous power of pathological oscillations in these loci, which
correlated well with zolpidem uptake and restoration of
function. These results suggest that speciﬁc motor and
cognitive impairments are related to increased low-fre-
quency oscillatory neuronal network activity, and that zol-
pidem is able to desynchronize such pathological low-
frequency activity, restoring cognitive and motor function
(for further details see Hall et al., 2010b).
Here, we have used low-dose zolpidem and
magnetoencephalography (MEG) to perform a mechanistic
evaluation of neuronal network activity of bilateral M1
cortices in early-stage, unilateral symptomatic, drug-naive
PD patients. We hypothesized that zolpidem would reduce
exaggerated cortical beta activity in PD patients and restore
the dynamic range of MRBD and PMBR. We found that
resting beta power contralateral to the symptomatic side is
raised in PD and that power was reduced by zolpidem,
while resting beta power ipsilateral to the symptomatic side
was increased by zolpidem. When we analyzed changes in
beta activity that accompany movement we found that
following zolpidem, MRBD and PMBR were similar on
contralateral and ipsilateral sides. This rebalancing of inter-
hemispheric oscillatory dynamics appears to correlate with
the symptomatic improvements aﬀorded by low-dose
zolpidem.EXPERIMENTAL PROCEDURES
Participants
Nine early-stage right-handed PD participants (three
females, six males with a mean age of 60.7 years,
range 56–68 years) were recruited prior to the initiation
of PD medication. All PD participants were recruited on
the basis that they exhibited unilateral symptoms only
and were assessed for symptomatic severity using the
part III motor examination of the Uniﬁed Parkinson’s
Disease Rating Scale (UPDRS).
In addition, nine right-handed healthy age-matched
control (AMC) participants were recruited, (ﬁve females,
four males with a mean age of 62.2 years, range
48–70 years), as a comparison for the measurement of
spontaneous oscillatory activity and the eﬀects of
zolpidem on neural activity.
Throughout, contralateral and ipsilateral hemispheres
were assigned with respect to symptom presentation in
PD or dominant hand in AMC.The study was performed in accordance with the
Declaration of Helsinki, and approved by the Ethics
Committee of the School of Life and Health Sciences at
Aston University, U.K. Written, informed consent was
obtained from all participants.Structural magnetic resonance imaging (MRI)
recordings
High resolution anatomical MR images were obtained
using a 3-Tesla MRI system (Siemens, Erlangen,
Germany). These structural brain scans were used for
anatomical co-registration of MEG data, using 3-
dimensional surface matching of the participants scalp
and localization coils (Adjamian et al., 2004).MEG recordings
Participants were seated in a 275-channel MEG system
(VSM Medtech, Coquitlam, British Columbia, Canada)
or 306-channel Elekta system (Neuromag Oy, Helsinki,
Finland), for a period of 10 min. VSM data were
acquired at a sampling rate of 1.2 kHz using a 3rd order
gradiometer conﬁguration with a 50-Hz notch ﬁlter and
anti-aliasing 1–600-Hz band-pass ﬁlter while Elekta data
were collected at 1 kHz with a 1–300-Hz band-pass ﬁlter.
In order to pool data collected from the two diﬀerent
MEG systems, data from individual participants were
normalized to the absolute value of ipsilateral beta
power and expressed as a percentage. This
normalization process allows data from the two systems
to be integrated without bias, but does preclude the
direct comparison of absolute beta power values from
PD patients and AMC participants.
Head position was monitored throughout MEG
recordings, by matching the digitized position of three
surface-mounted electromagnetic positioning coils (left
and right pre-auricular and nasion), which were then
monitored throughout the recording process to ensure
no participant moved more than 5 mm from starting
position during recording period.
Data were recorded during 1-min rest periods and
during ﬁnger movement tasks (Fig. 1A, B) designed to
localize left and right M1 cortices (Hall et al., 2011). Move-
ment-related activity was recorded as discrete 3-min
blocks. Participants were required to perform a visual
reaction time task, in which they responded as quickly
as possible to a change in ﬁxation cross color with button
press by abduction of either the left or right index ﬁnger.
Stimuli were presented with a mean inter-stimulus dura-
tion of 6 s, with randomized jitter of ±1 s, with a total of
30 responses (Fig. 1A, B). Muscle activity was recorded
using electromyography (EMG) (Delsys, Boston, MA,
USA) in the ﬁrst dorsal interosseus (FDI) muscle, which
controls index-ﬁnger abduction. At the end of the ﬁrst
recording session, participants were administered oral
zolpidem (0.05 mg/kg), consistent with previously
reported eﬀective sub-sedative doses (Hall et al.,
2010b). An identical second MEG recording session
was initiated 50 min after the zolpidem administration,
with participants required to repeat the same rest and
movement periods.
Fig. 1. Recording of human primary motor cortex (M1) activity. (A) Participants completed a simple bi-manual FDI response task in response to
visual cue. (B) Movement times were controlled and precisely recorded using a button press and EMG activity. (C) Data averaged with respect to
the onset of EMG activity associated with the ﬁnger abduction. M1 can easily be identiﬁed by the generation of the PMBR following the oﬀset of
movement, seen in this example at 0.5 s post movement. (D) Active and passive window comparisons were made based upon pre-movement
baseline and PMBR windows. (E) Single subject example of localized M1 cortex contralateral to movement (green) used as the location for virtual
electrode recordings.
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Previous studies have established that the post-
movement increase in oscillatory activity, the PMBR,
provides reliable localization of M1 hand area
contralateral to the side of movement (Jurkiewicz et al.,
2006; Hall et al., 2011). Therefore, in order to localize left
and right M1, we used the synthetic aperture magnetom-
etry (SAM) beamforming method (Vrba and Robinson,
2001; Hillebrand et al., 2005) to localize PMBR in M1 con-
tralateral to the side of movement (Fig. 1). With time-zero
deﬁned as the oﬀset of EMG activity associated with
abduction of the index-ﬁnger (Fig. 1A–C), the diﬀerence
image of the beta (15–35 Hz) frequency power between
a pre-movement period (2.5 to 1.5 s) and post-move-
ment period (0.5–1.5 s) was computed (Fig. 1D). Using
this approach, the 3-dimensional coordinates of the max-
imal t-score is a reﬂection of the neural generator of the
PMBR, which is robustly localized to the M1 hand area
contralateral to the side of the ﬁnger movement
(Jurkiewicz et al., 2006). The maximal t-value in the sen-
sorimotor cortex region provided the functional identiﬁca-
tion of M1 in each participant used as the location for
virtual electrode recordings (Fig. 1E). The power proﬁle
of the oscillatory activity was determined using a 7-cycle
Morlet wavelet time–frequency analysis of the virtual elec-
trode output over the 1–100-Hz range in frequency bins of
0.5 Hz.
A pharmaco-MEG approach, as previously described
(Hall et al., 2010a,b, 2011), was used to identify the
changes in M1 as a consequence of zolpidem
administration, visualized with power spectral density
(PSD) plots. Changes in beta power were analyzed overthe one-minute rest intervals, for the frequency (0.5 Hz
resolution) where maximal PSD amplitude was observed
in the pre-zolpidem condition in the 15–35-Hz range. In
addition, the role of the balance in amplitude of beta
power between hemispheres was determined by calculat-
ing the ratio of contralateral and ipsilateral beta before
and after zolpidem. All data values reported in the main
text are presented as mean ± S.D unless otherwise sta-
ted. Statistical diﬀerences in beta power as recorded
between hemispheres or hemispheric ratios, both before
and after zolpidem were determined by using paired t-
tests.
The changes in beta activity related to movement
were assessed at the individual beta peak. Results refer
to pre-movement at rest measured at a time point 3 s
before movement onset for 1 s, pre-EMG measured for
0.5 s immediately before movement. Post-EMG activity,
analogous to MRBD was determined as the ﬁrst point
following the visual cue in which the beta band power
fell below 2.5 standard deviations of the power in the
baseline period and measured for 0.5 s. Early
observations suggested that the duration of PMBR may
be extended in PD patients. Therefore, measurement of
PMBR was separated into an early-PMBR and late-
PMBR commencing 1 s and 2.5 s after movement onset
respectively.RESULTS
Robust localization of bilateral M1 was possible in eight of
the nine PD patients and all nine AMC participants. Data
collected from the remaining PD patient included
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localization of M1 and therefore these data were
excluded from further analysis. Overall, data were of
suﬃcient quality in all seventeen PD and AMC
participants to compare M1 resting state oscillations
pre- and post-zolpidem.Symptomatic severity and zolpidem related
improvements
Assessment with the UPDRS conﬁrmed that all nine PD
patients presented with unilaterally dominant symptoms
with varied levels of severity (UPDRS: mean
14.25 ± 5.0). In all cases, following zolpidem
improvements were observed in the overall severity of
the symptoms observed (UPDRS improvement: mean
7.5 ± 1.9; p= 0.006). Analysis of category revealed
signiﬁcant improvements in all UPDRS items except
14-speech (Fig. 2). Anecdotally, improvements were
also observed in handwriting ability as noted from
patient report and observation of consent form
signatures obtained prior to MEG acquisition (pre-drug)
and prior to MRI acquisition (post-drug).Resting beta power
In PD patients abnormally elevated beta oscillations
(15–35 Hz) were observed in contralateral M1 (Fig. 2A).
This activity was characterized by prominent high
amplitude irregular bursts. Irregular bursting activity was
also observed in ipsilateral hemisphere but was of much
lower amplitude (Fig. 3A).
PSD analysis of PD data revealed beta activity in both
contralateral and ipsilateral M1 (Fig. 3B). However, the
beta power recorded in contralateral M1 was
signiﬁcantly higher than that of the ipsilateral region
(180.29%, p= 0.003, Fig. 3B), consistent with previous
reports of exaggerated beta frequency activity in PD.
The frequency of the contralateral beta activity
(18.2 ± 5.73 Hz) was not statistically diﬀerent from the
frequency of the ipsilateral (22.1 ± 5.44 Hz) beta activityFig. 2. Improvements in UPDRS following zolpidem administration. (left pan
zolpidem administration (0.05 mg/kg). (right panel) Group mean UPDRS sco(p= 0.2). A peak at mu (10 Hz) frequency was only
observed in four of the nine controls and three of the
eight PD patients and therefore statistical analysis was
not carried out on this frequency. In AMC participants,
there was no statistical diﬀerence in the power of the
resting beta power recorded from the contralateral and
ipsilateral M1 (p= 0.33).Eﬀects of zolpidem on resting beta power
In PD participants, zolpidem reduced the power of
contralateral beta by 51.1 ± 45.6%, p= 0.016, Fig. 4A)
without signiﬁcant change in frequency (18.2–21.8 Hz,
p= 0.96). Conversely, zolpidem increased the power of
ipsilateral beta by 24.4 ± 31.9%, p= 0.004, Fig. 4B)
also without signiﬁcant change in mean peak frequency
(22.1–24.2 Hz, p= 0.27). The reduction in contralateral
and increase in ipsilateral beta power (Fig. 4A, B)
resulted in parity post zolpidem, (mean hemispheric
(contralateral/ipsilateral) power ratio: pre-zolpidem
1.8 ± 0.51; post-zolpidem 0.98 ± 0.21, p= 0.0004,
Fig. 4B) and no signiﬁcant diﬀerence between
hemispheres (p= 0.47).
This address the question of functional signiﬁcance
the ratio of contralateral to ipsilateral beta power was
determined for each patient before and after zolpidem
administration. This was compared with the UPDRS for
the corresponding patient (Fig. 4C). Calculation of
Pearson product moment revealed a strong and
signiﬁcant linear dependence between inter-hemispheric
M1 beta ratio change and UPDRS improvement
(r2 = 0.52, p= 0.040). Further analysis of linear
dependence between beta ratio and speciﬁc UPDRS
items revealed strongly signiﬁcant prediction of items
19: ﬁnger tapping (r2 = 0.59, p= 0.016) and 20: hand
movement (r2 = 0.48, p= 0.039).
Following zolpidem administration to AMC
participants there was no signiﬁcant change in either
contralateral beta power (2.89 ± 48.1%, p= 0.87) or
ipsilateral beta power (7.4 ± 42.1%, p= 0.61, Fig. 3A).
There was also no signiﬁcant change in the mean betael) Group mean UPDRS score (part III) before (dark) and after (light)
res for individual items before and after zolpidem administration.
Fig. 3. Increased beta power contralateral to PD impairment. (A) Synthetic aperture magnetometry (SAM) peaks (orange) in left and right M1 in
response to index ﬁnger movement (top panel). The middle panel shows representative band-pass ﬁltered (15–35 Hz) virtual electrode (VE) traces
of left and right M1 during passive rest periods. Prominent bursts of beta activity are seen in contralateral M1. (B) Power spectral density plots
showing the percentage power (normalized to ipsilateral) in M1 contralateral and ipsilateral to symptomatic limbs in PD (n= 8, left panel) and the
dominant hand in AMC (n= 9, right panel).
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1.03 ± 0.26, p= 0.35, Fig. 3B).Eﬀects of zolpidem on movement-related changes in
beta power
Finally, we tracked the absolute power changes that
occurred in M1 regions, both contralateral and ipsilateral
to symptom presentation, during the various phases of
cued movement. Speciﬁcally, we focused upon pre-
movement at rest, pre-EMG activity, post-EMG activity
(MRBD), early PMBR and late PMBR. Analysis of
absolute power at the peak-beta frequency in each
individual, pre- versus post-zolpidem, revealed
signiﬁcant diﬀerences in the contralateral hemisphere
pre-EMG (p= 0.026) and late PMBR (p= 0.044)
(Fig. 5A upper panel) and in the ipsilateral hemisphere
resting beta (p= 0.022), pre-EMG (p= 0.032) and late
PMBR (p= 0.042) were all signiﬁcantly diﬀerent
(Fig. 5A lower panel). In each case, low-dose zolpidem
had no signiﬁcant eﬀect on the post-EMG (MRBD). To
provide a temporal representation of the diﬀerencesobserved, a post hoc continuous t-test of beta power in
each sample was used to illustrate the periods of
signiﬁcant diﬀerence. These were then superimposed
upon the beta power proﬁles (Fig. 5).
A comparison of M1 contralateral and ipsilateral beta
power pre-zolpidem showed signiﬁcant diﬀerences at all
time points pre and post movement (rest, p= 0.022,
pre-EMG, p= 0.02, post-EMG, p= 0.016, early PMBR,
p= 0.039, late PMBR, p= 0.021, Fig. 5B upper panel).
In contrast, the contralateral versus ipsilateral beta
power post-zolpidem, showed no time points of
signiﬁcant diﬀerence (Fig. 5B lower panel). Hence,
zolpidem appeared to induce hemispheric parity in both
resting and movement-related dynamic beta.DISCUSSION
In this study we have shown prominent disparity in inter-
hemispheric resting beta power in the motor cortex in
early-stage PD participants. Furthermore, modulation of
GABAA receptors using zolpidem re-normalized inter-
hemispheric beta power such that the ratio approached
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Fig. 4. Zolpidem modulation of inter-hemispheric M1 beta ratio in PD at rest. (A) Histograms showing percentage change in group mean beta power
following administration of zolpidem in contralateral (light) and ipsilateral (dark) hemispheres in PD and AMC. (B) Mean ratio of beta power
(contralateral/ipsilateral) before and after zolpidem in PD patients (n= 8) and AMC (n= 9). ⁄p< 0.05, ⁄⁄p< 0.01, ⁄⁄⁄p< 0.001. (C) Correlation
between the change in inter-hemispheric beta ratio and change in UPDRS shows strong correspondence between ratio and severity (r2 = 0.52).
Fig. 5. Eﬀects of zolpidem on movement-related changes in beta activity. Comparative group images (n= 8) of beta power during the movement
task, where dotted line at time 0 indicates the onset of EMG activity. (A) Upper panel compares M1 beta power contralateral to symptom
presentation. Pre-zolpidem (blue) and post-zolpidem (green). The lower panel compares data from ipsilateral to symptom presentation. Pre-
zolpidem (red) and post-zolpidem (light blue). (B) The upper panel shows pre-zolpidem data from ipsilateral and contralateral hemispheres, while
the lower panel compares the data post-zolpidem. The speciﬁc time intervals indicated were used to assess diﬀerences in the pre-movement rest,
pre-EMG, post-EMG (MRBD), early (e) PMBR and late (l) PMBR. Shaded areas indicate periods of signiﬁcant diﬀerences as determined by a post
hoc continuous t-test of beta power.
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74 S. D. Hall et al. / Neuroscience 281 (2014) 68–76parity. These changes correlated with symptomatic
improvement. These changes in response to zolpidem
were also reﬂected in pre-movement beta
desynchronization and the late PMBR.Exaggerated contralateral beta power
For a number of years exaggerated beta oscillations have
been observed in subcortical structures such as STN and
globus pallidus in both PD patients and animal models of
PD (Brown and Marsden, 2001; Cassidy et al., 2002).
This increase in beta power is accompanied by increased
synchrony and coherence across networks and is thought
to limit computational capacity (Hammond et al., 2007)
through reduced information coding and consequent
inability to uncouple and re-recruit appropriate motor net-
works. However, in the cortex, pathologically exaggerated
oscillations have not been typically observed in PD
patients. This may be due to the fact that the majority of
studies focus on late-stage patients who are usually tak-
ing dopamine replacement therapies which are known to
reduce beta power (Silberstein et al., 2005; Kuhn et al.,
2006; Ku¨hn et al., 2009; Jenkinson and Brown, 2011) or
collapse of cortical beta generation in later stages of the
disease. The results presented here conﬁrm those in a
previous investigation in early-stage PD patients which
did report enhanced beta in M1 contralateral to the most
severely aﬀected side (Pollok et al., 2012). Anecdotally,
a number of the patients (e.g. Fig. 3B) exhibited
pronounced temporal ﬂuctuation in beta band power
(so-called bursting), which may be of importance with
regard to functional abnormalities as observed in previous
intraoperative recordings (Little et al., 2012).Hemispheric parity of beta power
At face value, the eﬀects of low-dose zolpidem on
contralateral beta power are analogous to that of
L-DOPA, with both drugs decreasing exaggerated beta
and thus removing a functional block allowing
appropriate desynchronization to take place prior to
movement. However, a recent report has indicated that
increased resting beta power is normal in healthy aging
(Rossiter et al., 2014), an eﬀect which is more pro-
nounced contralateral than ipsilateral to the dominant
hand. Given that most of the healthy-aged population do
not show parkinsonian symptoms, it seems unlikely that
exaggerated resting beta alone underlies PD symptoms.
In this context, most of the reports to date have investi-
gated beta power in PD on one side of the brain only,
due to clinical and/or methodological considerations. In
the current study, we have shown that, in contrast to the
inhibitory eﬀects of zolpidem on contralateral beta power,
ipsilateral beta power is augmented, resulting in an equal-
isation of inter-hemispheric power at rest. These data
suggest strongly that the inter-hemispheric power ratio
is a critical determinant and potential biomarker of symp-
tomatic PD. In support of this, in control participants, beta
power on both sides of the brain is augmented by zolpi-
dem, suggesting that beta power per se is irrelevant in
the context of PD, so long as the power is equably distrib-
uted bilaterally.This observation oﬀers a rather simplistic explanation
for drug-induced improvements in motor function;
however, it is worth considering the implications of
lateral equity in motor function. The performance of a
ﬁnger movement is accompanied by a reduction in beta
power that occurs bilaterally in the sensorimotor cortex
(Pfurtscheller and Berghold, 1989; Leocani et al., 1997).
While the general assumption is that the process of
desynchronization represents an uncoupling of units in
the contralateral hemisphere to engage and elicit a spe-
ciﬁc motor output, the consistent observation of this bilat-
eral modulation would suggest that interaction between
hemispheres is an intrinsic part of the process; imbalance
in this relationship therefore represents a potential prob-
lem for any dependent communication.
Zolpidem eﬀects on MRBD and PMBR
Our analyses of zolpidem-induced eﬀects on beta power
in relation to cued movement shows clear diﬀerences in
the pre-EMG, consistent with the observation of
elevated spontaneous beta power in M1 in PD.
However, we observed no signiﬁcant diﬀerence in
MRBD following zolpidem administration. This is
perhaps surprising, given that previous studies have
observed increases in MRBD during GABAergic
modulation (Hall et al., 2011; Muthukumaraswamy et al.,
2013). However, these ﬁndings are supportive of the sug-
gestion that movement generation is not mechanistically
dependent upon MRBD per se, as previous studies have
demonstrated independence of MRBD and motor function
(Hall et al., 2011; McAllister et al., 2013). The fact that
MRBD is not changed may indicate that MRBD is not a
driver of motor output or indeed that this motor output is
not impaired in early stage PD.
Functionally, it is possible that the zolpidem-induced
normalization of the pre-EMG represents resolution of a
cognitive load problem. In this scenario, diﬀerences in
the pre-EMG phase might be due to alterations in the
ability to plan before making the movement. Hence, the
preparatory pre-EMG phase could have a potential role
in the preparation and initiation of movement (i.e.
bradykinesia), with the amplitude of synchronization
before movement being related to the size of the
network recruited to achieve the force required.
Here, we observe that early-PMBR appears unaﬀected
by zolpidem, consistent with our previous observation that
GABAergic modulation does not modify the amplitude of
this feature (Hall et al., 2011). However, we observe signif-
icant diﬀerences in late-PMBR, which remains elevated for
several seconds in the pre-zolpidem condition. Function-
ally, if elevated beta power is problematic for the initiation
of movement, this may compound the problem of making
continual, smooth movements because disengagement
from previous motor programs may be impaired. Equally,
the change in this feature may represent an eﬀect, rather
than a cause, of improvement in movement.GABA-mediated network changes
The method used here does not oﬀer the sensitivity to
determine whether changes in beta power are the direct
S. D. Hall et al. / Neuroscience 281 (2014) 68–76 75result of GABA modulation of M1 or secondary eﬀects of
GABA modulation in sub-cortical regions or both.
However, evidence from rodent M1 models
demonstrates that M1 beta is increased following
zolpidem (100 nM) administration through increased
phasic interneuron drive (Yamawaki et al., 2008, consis-
tent with previously described models, see Whittington
et al., 1995; Traub et al., 1996). Furthermore, recent work
describes how zolpidem produces dose-speciﬁc eﬀects
on oscillations in M1 through an alpha-1 subunit-mediated
reduction in beta power at low concentration of 10 nM and
increased beta power at concentrations above 30 nM, the
eﬀects of low-dose zolpidem being mediated by selective
modulation of interneuron-speciﬁc tonic current (Prokic
et al., unpublished observation).
CONCLUSION
We have shown that low-dose zolpidem improves PD
symptoms, reduces exaggerated pathological
contralateral M1 cortical beta and increases ipsilateral
beta power resulting in parity of hemispheric beta power
ratio which directly correlates with symptom severity.
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